NASDAQ: BIOLBiolase Inc Stock
$0.15+0.00 (+0%)
Updated Apr 18, 2024
BIOL Price
$0.15
Fair Value Price
N/A
Market Cap
$4.81M
52 Week Low
$0.13
52 Week High
$33.44
P/E
-0.01x
P/B
-19.49x
P/S
0.03x
PEG
N/A
Dividend Yield
N/A
Revenue
$49.16M
Earnings
-$20.63M
Gross Margin
34%
Operating Margin
-37.1%
Profit Margin
-76.5%
Debt to Equity
-134.19
Operating Cash Flow
-$14M
Beta
1.16
Next Earnings
May 9, 2024
Ex-Dividend
N/A
Next Dividend
N/A
BIOL Overview
BIOLASE, Inc., together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, such as cosmetic, restorative, and complex surgical applications. The company offers Waterlase all-tissue dental laser systems for cutting soft and hard tissues; diode soft-tissue laser systems for soft tissue, pain therapy, teeth whitening, and cosmetic procedures; and Epic Hygiene laser to manage non-surgical periodontitis and enhance clinical production. It also manufactures and sells consumable products and accessories for its laser systems, as well as markets flexible fibers and hand pieces, and teeth whitening gel kits. The company sells its products through its field sales force and distributor network. The company was formerly known as BIOLASE Technology, Inc. and changed its name to BIOLASE, Inc. in 2012. BIOLASE, Inc. was founded in 1984 and is headquartered in Foothill Ranch, California.
Zen Score
–
Industry Average (27)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how BIOL scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
BIOL is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
BIOL is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
BIOL's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more BIOL due diligence checks available for Premium users.
Be the first to know about important BIOL news, forecast changes, insider trades & much more!
BIOL News
Valuation
BIOL fair value
Fair Value of BIOL stock based on Discounted Cash Flow (DCF)
Price
$0.15
Fair Value
$20.79
Undervalued by
99.28%
BIOL is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
BIOL price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.01x
Industry
28.61x
Market
41.33x
BIOL price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-19.49x
Industry
3.63x
BIOL's financial health
Profit margin
Revenue
$13.5M
Net Income
-$5.3M
Profit Margin
-165.4%
BIOL's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
BIOL's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$35.1M
Liabilities
$33.1M
Debt to equity
-134.19
BIOL's short-term assets ($24.86M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BIOL's short-term assets ($24.86M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BIOL's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
BIOL's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.3M
Investing
-$3.0k
Financing
$885.0k
BIOL's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
BIOL vs Medical Device Stocks
Biolase Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.